Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Researchers hunt for proteins that control age-related inflammation

Researchers hunt for proteins that control age-related inflammation

New Capabilities

Geroscience builds its toolkit of molecular targets, one protein at a time

5 days ago: Inflammaging finding enters wider news cycle

Overview

Chronic, low-grade inflammation builds up with age and drives many of the diseases that come with growing old. A team at the University at Buffalo says they've found a protein, tristetraprolin, that pumps the brakes on it. When they boosted the protein in older mice, the animals grew stronger and had healthier bones than untreated peers.

The finding adds a concrete molecular target to geroscience, the field trying to treat aging itself instead of the diseases it causes. If the mouse results hold up in people, future therapies could slow age-related decline across the board rather than one disease at a time.

Why it matters

If geroscience finds the right molecular brakes on inflammation, age-related decline could become something you prevent, not just manage disease by disease.

Key Indicators

$2.1M
NIH grant
National Institutes of Health funding behind the Buffalo TTP study.
6 yrs
Research runway
Length of the Buffalo lab's tristetraprolin project before publication.
Mice
Stage
Preclinical only. No human trials of TTP modulation for aging exist yet.
26 yrs
Since 'inflammaging' was named
Italian immunologist Claudio Franceschi coined the term in 2000.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

June 2000 May 2026

9 events Latest: 5 days ago
Tap a bar to jump to that date
  1. Inflammaging finding enters wider news cycle

    Latest Coverage

    ScienceDaily and other outlets amplify the TTP results, framing them as a concrete molecular target for slowing age-related decline.

  2. TTP study published

    Publication

    Aging and Disease publishes the Buffalo paper showing boosted TTP makes older mice stronger and healthier.

  3. Buffalo TTP project begins

    Research

    Kirkwood's lab starts its six-year NIH-funded study of tristetraprolin in aging.

  4. First human senolytic pilot

    Clinical

    A small open-label trial tests senolytic drugs in patients with idiopathic pulmonary fibrosis.

  5. TAME trial proposed

    Trial design

    Nir Barzilai proposes Targeting Aging with Metformin, a US trial to test whether a generic drug can delay multiple age-related diseases.

  6. Senolytics shown in mice

    Preclinical

    James Kirkland's Mayo Clinic team reports that drugs clearing senescent cells improve healthspan in old mice.

  7. Geroscience consensus published

    Field-defining

    A Cell paper formalizes geroscience: target aging mechanisms, treat many diseases at once.

  8. Rapamycin extends mouse lifespan

    Preclinical

    A Nature paper shows rapamycin, an mTOR inhibitor, lengthens life in elderly mice. Geroscience gains its first widely cited proof of concept.

  9. Franceschi coins 'inflammaging'

    Concept

    Italian immunologist Claudio Franceschi names the chronic low-grade inflammation of aging and frames it as a shared driver of age-related disease.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

April 2015

Senolytics shown to extend mouse healthspan (2015)

James Kirkland's team at Mayo Clinic reported in Aging Cell that a combination of dasatinib and quercetin selectively killed senescent cells in old mice, improving cardiovascular function and physical performance. The paper triggered a wave of geroscience startups and human pilot studies.

Then

Two biotechs, Unity Biotechnology and Cleara Biotech, formed within two years. The first human pilot launched in 2018 in patients with idiopathic pulmonary fibrosis.

Now

Senolytics remain in human trials a decade later, with mixed results. No senolytic has won FDA approval for an aging indication.

Why this matters now

Same arc as the TTP finding: clean mouse data, fast pharma interest, slow translation. Reads as the most direct template for what comes next.

July 2009

Rapamycin extends mouse lifespan (2009)

A Nature paper from the NIH Interventions Testing Program showed rapamycin extended lifespan in elderly mice by 9 to 14 percent. The drug, originally an immunosuppressant for transplant patients, became the highest-profile longevity candidate in mainstream science.

Then

Off-label rapamycin use spread among biohackers and a small number of physicians within five years. The PEARL trial began testing it in humans in 2020.

Now

Rapamycin has not won an FDA aging indication. Its side effect profile and regulatory caution have kept it stuck despite consistent mouse results.

Why this matters now

Shows the gap between strong mouse biology and accepted human therapy. TTP modulation would have to cross the same gap, which has held up rapamycin for over fifteen years.

1976

Akira Endo isolates the first statin (1976)

Japanese biochemist Akira Endo isolated compactin from a Penicillium fungus while screening for cholesterol-lowering compounds. The molecule blocked the enzyme HMG-CoA reductase and became the prototype for the statin class.

Then

Compactin showed cholesterol-lowering effects in animals and small human studies through the early 1980s but was dropped over safety concerns.

Now

Merck's lovastatin won FDA approval in 1987, eleven years after Endo's discovery. Statins later became one of the most prescribed drug classes in the world.

Why this matters now

When a single molecular target really does control a chronic process, the payoff can be enormous, but rarely arrives in under a decade. TTP, if real, is at year zero of that arc.

Sources

(9)